Literature DB >> 18533760

An evidence-based medicine strategy for achieving remission in bipolar disorder.

John L Beyer1.   

Abstract

Controlled trials have demonstrated the efficacy of several classes of drugs for achieving acute response in bipolar mania and depression. For many years, clinical response has been the primary outcome in the majority of short-term efficacy studies. However, there is a growing consensus that the optimal goal in the long-term management of bipolar disorder is remission. The purpose of this article is to briefly summarize the clinical importance of remission in bipolar disorder and to review data on the effectiveness of available treatments for achieving and sustaining remission.

Entities:  

Mesh:

Year:  2008        PMID: 18533760

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  5 in total

1.  Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder.

Authors:  Izabela Guimarães Barbosa; Rodrigo Barreto Huguet; Vanessa Amaral Mendonça; Lirlândia Pires Sousa; Fernando Silva Neves; Moisés Evandro Bauer; Antônio Lúcio Teixeira
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-05-06       Impact factor: 5.270

2.  LICAVAL: combination therapy in acute and maintenance treatment of bipolar disorder.

Authors:  Rodolfo N Campos; Luis F Costa; Danielle S Bio; Márcio G Soeiro de Souza; Carla R L Garcia; Frederico N Demétrio; Doris H Moreno; Ricardo A Moreno
Journal:  Trials       Date:  2010-06-23       Impact factor: 2.279

Review 3.  Lurasidone for the treatment of bipolar depression: an evidence-based review.

Authors:  Rachel Franklin; Sam Zorowitz; Andrew K Corse; Alik S Widge; Thilo Deckersbach
Journal:  Neuropsychiatr Dis Treat       Date:  2015-08-19       Impact factor: 2.570

4.  The ARIQUELI study: potentiation of quetiapine in bipolar I nonresponders with lithium versus aripiprazole.

Authors:  Giovani Missio; Doris Hupfeld Moreno; Fernando Fernandes; Danielle Soares Bio; Márcio Gehardt Soeiro-de-Souza; Domingos Rodrigues dos Santos; Denise Petresco David; Luis Felipe Costa; Frederico Navas Demétrio; Ricardo Alberto Moreno
Journal:  Trials       Date:  2013-06-27       Impact factor: 2.279

Review 5.  Lurasidone as a potential therapy for bipolar disorder.

Authors:  Young Sup Woo; Hee Ryung Wang; Won-Myong Bahk
Journal:  Neuropsychiatr Dis Treat       Date:  2013-10-08       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.